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introduction: Not all newly created arteriovenous fistulas (AVFs) successfully mature 
and develop into a functioning access for hemodialysis. Percutaneous transluminal 
angioplasty (PTA) and balloon-assisted maturation (BAM) have been utilized to either 
treat flow-limiting stenoses or to promote and accelerate maturation. We hypothesized 
that unusable upper arm AVFs can be rescued by conversion to a functional access 
using the percutaneous placement of a stent graft (SG).
Methods: Clinical data on 12 patients with an early non-usable upper arm AVF under-
went percutaneous revision using SGs. There were six brachial–cephalic, three brachial–
basilic, and three brachial–brachial vein transposition AVFs.
results: All patients had either at least two or more stenoses (>2 cm) within the fistula 
conduit, or a long segment stenosis (>4 cm) in combination with shorter segment ste-
noses. Nine patients had failed PTA. Three patients had failed BAM at outside access 
centers. All patients were referred for failure to achieve access cannulation and con-
comitant hemodialysis through the AVF. SGs were placed retrograde toward the arterial 
anastomoses and ranged in diameter (6, 7, and 8 mm in four, seven, and one patients, 
respectively). The average length of the SG was 10 cm (range 5–15 cm). All SGs were 
post-balloon dilated at the time of placement. All AVFs were salvaged, and patients were 
able to maintain functional use of their access with cannulation occurring through the SG. 
The primary patency rate at 6 and 12 months was 91% [95% confidence interval (CI), 
56–98%] and 65% (95% CI, 32–87%), respectively (n = 11 and 5 at risk, respectively). 
The secondary patency rate at 6 and 12 months was 100 and 72% (95% CI, 46–93%), 
respectively (n = 11 and 7 at risk, respectively).
conclusion: This report outlines a successful initial experience using SGs to rescue, 
preserve, and convert an unusable upper arm AVF into a functioning hemodialysis 
access.
Keywords: hemodialysis access, arteriovenous fistula, stent graft, Viabahn, fistula stenosis, dialysis access 
salvage
Table 2 | interventions on the arteriovenous fistula access prior to stent 
graft placement.
interventions number (%)
Percutaneous transluminal angioplasty 9 (75)
Balloon-assisted maturation 3 (25)
Table 1 | Patient demographics, comorbidities, and type of 
arteriovenous fistula (aVF) present.
Patient characteristics number (%)
Women 7 (58)
Men 5 (42)
End-stage renal disease on dialysis 12 (100)
Congestive heart failure 3 (25)
Hypertension 11 (92)
Diabetes 11 (92)
Hyperlipidemia 4 (33)
Stroke 4 (33)
Type of aVF
Brachial–cephalic 6 (50)
Brachial–basilic vein transposition 3 (25)
Brachial–brachial vein transposition 3 (25)
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inTrODUcTiOn
A patent functioning hemodialysis access, either graft or fistula, is 
critical in ensuring effective treatment for patients with end-stage 
renal disease. The implementation of clinical practice guidelines 
of the Dialysis Outcome Quality Initiative (K/DOQI) (1) has lead 
to movement toward a fistula-first initiative and an overall reduc-
tion in mortality for patients on hemodialysis.
The literature on the outcome of the use of stent grafts (SGs) 
in salvaging failed arteriovenous (AV) accesses is limited. Several 
studies have reported the outcomes for the use of bare metal stents 
and SGs to treat venous stenoses that exhibit elastic recoil after 
balloon angioplasty (2–5). Shemesh and colleagues (6) published 
a randomized prospective study suggesting that the use of SGs 
may be superior to bare metal stents for the treatment of cephalic 
arch stenoses in autogenous AV accesses.
The purpose of this case series is to examine the outcome of 
attempted salvage of early non-usable (primary non-maturation) 
AV fistulae (AVF) with SGs.
MaTerials anD MeThODs
study Design
This was a retrospective review of 12 patients who underwent 
placement of an SG for non-usable AVF (primary non-matura-
tion) over a 2-year period. The Viabahn® Endoprosthesis (W.L. 
Gore and Associates, Inc., Flagstaff, AZ, USA) was utilized in all 
cases. Collected data included patient demographics and medical 
comorbidities, along with dimensions of the SG placed. Hospital 
and clinic records were reviewed, and patients contacted to obtain 
follow-up data as part of an Institutional Review Board-approved 
protocol.
study setting
This study was performed in an academic medical center with 
1,000 beds in a catchment area of 5 million people. During 
the study period, a total of 672 primary AVF creations were 
performed.
study Population
Twelve patients (58% women; mean age 65 ±  10  years, range 
46–81  years) who presented with a non-usable and/or aban-
doned AVF. The demographics, comorbidities, and type of AVF 
are described in Table 1. Nine patients had failed percutaneous 
transluminal angioplasty (PTA) (n = 9) to correct documented 
stenosis. Three patients had balloon-assisted maturation (BAM) 
attempted at outside access centers and failed (Table  2). The 
indication for SG placement in this group was access preservation 
and use.
Technique
A single retrograde ultrasound-guided puncture technique was 
utilized at the hemodialysis site to access the fistula. In general, 
a fistulogram was performed to delineate and characterize the 
areas of stenoses. Often, retrograde access into the brachial 
artery was required and achieved by manipulating a 0.035-mm 
angled glide wire (Terumo, Somerset, NJ, USA) from the venous 
stick into the brachial artery and then advancing a 4-Fr glide 
catheter (Glidecath®, Terumo) to perform an arteriogram with 
concomitant imaging of the AVF (Figure 1). This proved appreci-
ably useful in instances where a juxta-anastomotic stenosis was 
present. Once the treatment area was identified, selection of the 
SG diameter was tailored to accommodate the diameter of the 
native fistula at the normal or stenosis-free segment. The Viabahn 
Endoprosthesis is a flexible, self-expanding nitinol stent lined 
with expanded polytetrafluoroethylene (ePTFE) that is approved 
to treat superficial femoral arterial occlusive disease. The SG was 
positioned and deployed with post-deployment angioplasty. Care 
was taken not to cross the SG into the arterial anastomosis in 
all cases. Technical success was routinely defined by completion 
fistulogram in Figure 2. Patients were typically discharged on the 
day of the procedure after clinical assessment and were assessed 
during routine follow-up with clinical success defined as success-
ful dialysis access use. Typically the treated fistula was accessed 
within 2 weeks of the procedure. We postulate that this period of 
time allows for the inflammatory reaction generated by the SG to 
add to the venous and tissue wall thickness surrounding the SG.
Dialysis units were cleared to access the AVF through the segment 
of the vein containing the SG, thus directly puncturing through the 
graft. The duration of successful use of the access was determined 
from patient history and physical examination at the outpatient 
clinic visits. None of the patients had reports of incomplete or sub-
optimal dialysis treatments from the dialysis units. Duplex scans 
were not performed routinely when the AV access was functioning 
without clinical evidence of stenosis or malfunction.
Definitions
Primary patency (PP) was defined as the time from SG placement 
until first access failure or intervention aimed at maintaining 
FigUre 1 | right brachial–basilic vein transposition fistulogram. A 4-Fr glide catheter is shown advanced retrograde into the brachial artery (large arrow) to 
perform an arteriogram with concomitant imaging of the arteriovenous fistula and its multiple areas of stenosis (small arrows).
FigUre 2 | (a) Brachial–cephalic arteriovenous fistula with short-segment (arrow) and long-segment (bracket) areas of stenosis. (b) Retrograde fistulogram 
showing successful treatment with a 7 mm × 15 cm Viabahn SG.
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Table 3 | Diameter and length measurements of the implanted stent 
grafts.
Device characteristics number (%)
Diameter (mm)
6 4 (33)
7 7 (59)
8 1 (8)
length (mm)
5 1 (8)
10 8 (67)
15 3 (25)
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patency. Secondary patency (SP) was defined as the interval from 
SG placement to abandonment of fistula. Clinical success was 
defined as preservation of AV access after the outflow restoration 
with covered stent placement in the AVF. The patient’s status 
after discharge was followed through clinic records, and patients 
were seen in clinic and evaluated by physical exam. They were 
contacted to determine access complications and patency since 
their last visit at our institution. Survival was also confirmed by 
querying the Social Security Death Index.
statistical analysis
Measured values are reported as percentages or means ±  SD 
where appropriate. The patency rates were calculated by Kaplan–
Meier analysis.
resUlTs
At the time of presentation, all patients were on hemodialysis 
through a tunneled dialysis catheter. All patients had a previously 
created but unusable AVF. The mean duration of the access was 
3.6  months (range 2–4.5  months). Intraoperative venograms 
did not demonstrate central venous stenoses or arterial inflow 
disease in any of the patients. There were six brachial–cephalic 
upper arm, three brachial–basilic upper arm, and three brachial–
brachial with vein transposition AVFs. The brachial–basilic and 
brachial–brachial AVF were two-stage procedures. All patients 
were referred for failure to achieve access cannulation and con-
comitant hemodialysis through the AVF. Patients had either at 
least two or more stenoses (>2  cm) within the fistula conduit, 
or a long segment stenosis (>4 cm) in combination with shorter 
segment stenoses. Nine patients had failed PTA. Three patients 
had failed BAM at outside access centers.
Stent graft sizes used were 6, 7, and 8 mm in diameter in four, 
seven, and one patients, respectively. The average length of the SG 
was 10 cm (range 5–15 cm) (Table 3). All SGs were post-balloon 
dilated at the time of placement. Technical success was achieved 
in all cases (100%); no residual stenosis was observed. There were 
eight AVF localized to the left upper arm and four to the right. 
Mean follow-up was 11 ± 7 months. There was no perioperative 
mortality. Seventy-eight percent of patients were alive at 1 year. 
The PP rate at 6 and 12 months was 91% [95% confidence interval 
(CI), 56–98%] and 65% (95% CI, 32–87%), respectively (n = 11 
and 5 at risk, respectively). The SP rate at 6 and 12 months was 
100 and 72% (95% CI, 46–93%), respectively (n =  11 and 7 at 
risk, respectively). None of the patients had access-related com-
plications such as erosion or infection. One patient at long-term 
follow-up was found to have a pseudoaneurysm at the site of 
dialysis access puncture, which was repaired with placement of 
an SG.
DiscUssiOn
The “failing to mature” AVF can be defined as a surgically created 
AVF that failed to properly expand without stenosis and become 
usable for the purpose of hemodialysis within 8–12 weeks after 
its creation (7). This failure could clinically manifest as difficulty 
in cannulation, low flows, or both. The “failing to mature” AVF 
is caused by intrinsically poor native vessels or by post-surgical 
derangements. In this series, the AVF failed to mature exclusively 
due to venous stenosis within the AVF segment. The fistula-first 
initiative as per the KDOQI guidelines has led to creation of more 
native fistulas as primary access, in effect leading to the increase 
in incidence of primary failure rates ranging between 23 and 
48% (8–14). Lower maturation rates may effectively reduce the 
functional patency of an AVF to a level approaching that of pros-
thetic AV grafts (15). Failure of maturation also means protracted 
hemodialysis through tunneled catheters, increasing the risk of 
infectious complications, and central venous stenosis (11).
Numerous techniques have been used to improve fistula func-
tion by addressing the cause of malfunction, including venous 
and arterial angioplasty, stent placement, thrombectomy, venous 
branch ligation, fistula superficialization, banding, interposition 
vein grafts, transposition, and extensive preoperative imaging 
(16–18). The technique of BAM needs special mention as a 
commonly used therapeutic technique to help facilitate fistula 
maturation, with reported success up to 85% (19). However, 
there is a lack of evidence describing the use of long-segment 
SGs to salvage unusable AVFs that have failed previous rescue 
attempts with PTA or BAM. All patients who underwent SG 
placement in our series had failed salvage treatment by the latter 
two techniques.
In the setting where a venous stenosis exhibits significant 
elastic recoil following angioplasty, the use of a stent is recom-
mended to maintain luminal diameter and improve patency. In 
an early series by of eight patients with multiple AV graft failures, 
Naoum and colleagues (20) placed self-expanding nitinol stents 
for the treatment of a venous outflow stenosis and showed a 25% 
SP at 6 months. However, bare stents stimulate proliferation of 
intimal hyperplasia, leading to in-stent stenosis and eventual 
failure. The long-term results with the use of stents for the treat-
ment of venous stenoses in AVF are similar to those obtained 
with angioplasty alone (21). SGs, however, have shown to have 
superior SP rates at 6 months compared to angioplasty alone in 
the setting of failing AVG (22).
Vesely and colleagues (23) retrospectively studied 51 
patients who underwent angioplasty of a graft-related stenosis 
and required salvage with either a bare stent or SG. The PP of 
the vascular access was 81, 70, and 54% at 1, 3, and 6 months, 
respectively. The SP was 89, 82, and 74% at 3, 6, and 12 months, 
respectively. The authors concluded that bare stents and SG 
are useful in salvaging failed angioplasty procedures and 
FigUre 3 | algorithm for salvage of unusable aVFs and conversion to 
a stentula. AVF, arteriovenous fistula; US, ultrasound; PTA, percutaneous 
transluminal angioplasty; BAM, balloon-assisted maturation.
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maintaining patency of the hemodialysis graft. Furthermore, 
Viabahn SG has been shown to improve the patency of fail-
ing hemodialysis grafts with either venous outflow stenosis or 
occlusion. Stent-graft patency was 94.7 and 82.1% at 12 and 
24 months, respectively. SGs improved freedom from reinter-
vention rates and overall patency rates of failing AVGs (24). 
Similarly, in a retrospective review of 44 patients with failing 
AVGs, 11 were treated with PTA alone and 33 with the place-
ment of a Viabahn SG. At 12 months, 87.8% of grafts treated 
with SG were functional compared to 36.4% of those with PTA 
alone (25). Cephalic arch stenosis is a cause of dysfunction in 
autogenous AVFs that often require multiple reinterventions 
with angioplasty. Shawyer and associates inserted six Viabahn 
SGs to treat residual stenosis after angioplasty and five for 
angioplasty induced rupture. Primary access patency rates were 
81.8% at 6 months and 72.7% at 12 months (26). These reports 
demonstrate that SG can improve patency rates beyond those 
achieved with successful or for the treatment of failed PTA. 
More importantly, as in our series, SG can salvage the access 
and extend its use for hemodialysis.
Our use of SG in the setting of abandoned AVF for primary 
non-maturation is unique in its description and indication 
of use. We postulate that a 2-week maturation period of the 
access is needed to allow what we believe is the inflammatory 
response to generate thickening of the vessel wall and tissues 
in contact with the SG segment. We believe that this may con-
tribute to decreased needle site bleeding following cannulation 
required during hemodialysis treatment. Our patency rates at 
12 months compare favorably with the above cited reports.
Pseudoaneurysm formation at the site of access puncture is 
a foreseen complication associated with the use of ePTFE SG. 
Pseudoaneurysms are more commonly seen with ePTFE AVG 
for dialysis. Multiple reports describe repeated needle cannula-
tion of dialysis grafts—particularly at the same location—leading 
to damage and breakdown of the graft material and subsequent 
pseudoaneurysm formation (27, 28). A systematic rotation of 
needle punctures to alternate sites may prove beneficial in this 
instance (29).
This retrospective case series reports the successful initial 
experience using SGs to rescue early unusable AVFs, converting 
them into a functioning hemodialysis access with no procedural 
related mortality or morbidity. With this revision, all access can-
nulation for hemodialysis occurs through the segment contain-
ing the SG. We propose a new name for this novel technique: a 
“Stentula” (SG and fistula).
Limitations of this study include a small sample size, a retro-
spective analysis of the database, and a non-randomized study 
population. With such a small set of patients at the reported 
time points, the Kaplan–Meier estimates can be misleading 
and should be interpreted with caution. We realize that further 
work needs to be carried out to validate this initial early expe-
rience in this subset of dialysis patients. Based on this early 
experience, we propose an algorithm to guide the selection 
and treatment of patients for this procedure (Figure 3). This 
novel solution to treat failing or non-maturing abandoned 
AVFs cements the clinical utility of combining an SG with a 
fistula.
cOnclUsiOn
Use of SGs to treat complications of dialysis access has been 
well documented. Our description and use in a failing to 
mature AVF plagued with stenoses is unique, safe, and yields 
patency rates that allow access salvage and its maintenance 
for hemodialysis. However, more studies and longitudinal 
follow-up are needed to validate the initial findings of this 
technique.
eThics sTaTeMenT
Study data was obtained via a retrospective review of the 
patient’s medical records and standardized telephone inter-
views conducted with the patient as part of an IRB-approved 
protocol using preexisting data in a HIPAA compliant 
manner.
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